CAR T-Cell Payment Codes Don’t Address True Cost – OncLive
OncLive |
CAR T-Cell Payment Codes Don't Address True Cost
OncLive CMS's initial payment codes for chimeric antigen receptor (CAR) T-cell therapies are opposed by the medical community on the basis that they would be cumbersome to implement and wouldn't reflect the full amount of care delivered to each patient. |
